CLRB

CLRB

USD

Cellectar Biosciences Inc. Common Stock

$3.510+0.020 (0.573%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$3.490

Hoch

$3.560

Tief

$3.465

Volumen

0.02M

Unternehmensfundamentaldaten

Marktkapitalisierung

11.2M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.19M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $3.17Aktuell $3.510Hoch $66

Ähnliche Nachrichten

GlobeNewswire

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of

Mehr anzeigen
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
GlobeNewswire

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of

Mehr anzeigen
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
GlobeNewswire

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the "company"), a late-stage biotechnology company focused on the discovery and development of drugs for

Mehr anzeigen
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.